CDK6 Knockout Cell Line (HEK 293)

The choice depends on whether you are studying CDK6's role as a G1/S phase kinase or modeling CDK4/6 inhibitor pharmacology for breast cancer therapy. The Knockout line is the standard tool for asking whether CDK6 is required for these processes — CDK6 partners with D-type cyclins (CCND1, CCND2, CCND3) to phosphorylate RB1 at G1/S transition, releasing E2F transcription factors for S-phase gene expression; CDK6 has substantial functional overlap with CDK4 but also distinct functions in hematopoietic differentiation, glucose metabolism, and AML. Overexpression is useful for studying CDK6 gain-of-function effects. Important consideration: CDK4 and CDK6 share substantial substrate scope — single CDK6 knockout may show modest phenotypes if CDK4 compensates. This product complements the parallel CDK4 Knockout in HEK293 (also available) for paralog-specific dissection. Rescue with wild-type or kinase-dead CDK6 is the standard specificity control. The knockout is a critical specificity tool for ⭐⭐⭐ palbociclib (Ibrance, FDA-approved 2015 for HR+/HER2− metastatic breast cancer), ribociclib (Kisqali), abemaciclib (Verzenio) — three FDA-approved CDK4/6 inhibitors that have transformed HR+ breast cancer treatment — and emerging CDK6-selective inhibitors and CDK6 degraders.

Primary applications: • RB phosphorylation: phospho-RB1 (S780, S795, S807/811) Western blot to characterize CDK6 kinase activity. • G1/S progression: flow cytometry cell cycle analysis in CDK6-null versus rescued cells. • CDK4/6 paralog dissection: parallel analysis with CDK4 Knockout in HEK293 (also available) for paralog-specific characterization. • CDK4/6 inhibitor specificity: critical genetic control for palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Verzenio). EDITGENE recommends this model as a critical specificity control for FDA-approved CDK4/6 inhibitors in breast cancer therapy.

Yes. CDK6 rescue experiments are well-established for breast cancer drug research: • Construct design: use a codon-modified CDK6 sequence with a small C-terminal tag (FLAG, HA). CDK6 has the canonical CDK architecture (PSTAIRE motif in helix αC, T-loop with T177 activation phospho-site) — preserve all elements. • Kinase-dead rescue: K43R mutation in the ATP-binding lysine abolishes catalytic activity. • CDK4/6 inhibitor-resistant rescue: T-loop or gatekeeper residue mutations can confer palbociclib/ribociclib/abemaciclib resistance for on-target validation studies. • Functional readout: rescue should restore Cyclin D-CDK6 kinase activity and phospho-RB1 (S780, S795). HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for systematic CDK4/6 inhibitor research.